A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Trial Profile

A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LIXILAN JP-L
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 22 Aug 2018 to 3 Oct 2018.
    • 10 Aug 2017 Planned primary completion date changed from 22 Aug 2018 to 3 Oct 2018.
    • 13 Jul 2017 Planned End Date changed from 1 Jul 2018 to 22 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top